福元医药(601089.SH)：兰索拉唑肠溶胶囊获得药品注册证书

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received the drug registration certificate from the National Medical Products Administration for Lansoprazole enteric-coated capsules, indicating approval for production [1] Company Summary - The approved Lansoprazole enteric-coated capsules are available in two specifications: 15mg and 30mg [1] - Lansoprazole was developed by Takeda and was first approved for sale in France on December 31, 1990 [1] - The drug was approved for domestic sale in China on December 6, 1996, and is indicated for conditions such as gastric ulcers, duodenal ulcers, gastroesophageal reflux disease, Zollinger-Ellison syndrome, and anastomotic ulcers [1] Industry Summary - The approval of Lansoprazole enteric-coated capsules reflects ongoing regulatory support for pharmaceutical products aimed at treating gastrointestinal disorders [1]